A sustainable nanotechnology approach for finerenone detection using green-synthesized silver nanoparticles
Source abstract
Abstract
Abstract Finerenone, a third-generation selective non-steroidal mineralocorticoid receptor antagonist, is used in the management of diabetic kidney disease, with its efficacy further extended to reducing cardiovascular events in clinical trials. Silver nanoparticles (AgNPs) have received considerable attention for analytical and sensing applications because of their distinctive optical and surface properties, particularly surface plasmon resonance. In this study, AgNPs were green synthesized by the reduction of silver ions using gallic acid in basic media. The NPs were then characterized using dynamic light scattering and transmission electron microscopy, revealing an average size in the range ~ 10–30 nm and the zeta potential to be − 28 mV indicating the stability of the nanoparticles. The synthesized AgNPs were then employed in the determination of finerenone in bulk by correlating the decrease in absorbance at 394.5 nm with drug concentration. The method was linear in the range 6.00 × 10 –7 –6.00 × 10 –6 M with a limit of detection of 1.96 × 10 –7 M and a limit of quantification of 5.94 × 10 –7 M. The proposed approach was validated in accordance with International Council for Harmonization (ICH) requirements and successfully applied to the quantification of finerenone in both marketed dosage forms and spiked human plasma samples. Furthermore, the analytical eco-scale was used to assess the method’s greenness, and it demonstrated excellent compliance with green analytical chemistry (GAC) principles. Graphical abstract
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Biosensors and Analytical Detection · Analytical Methods in Pharmaceuticals · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12:2032. https://doi.org/10.2215/CJN.1149111610.2215/CJN.11491116 ↗
2. Fried LF, Folkerts K, Smela B, Bowrin KD, Mernagh P, Millier A, Kovesdy CP (2021) Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care 27:S168–S177. https://doi.org/10.37765/AJMC.2021.8866010.37765/AJMC.2021.88660 ↗
3. Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A (2022) Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant 37:1014–1023. https://doi.org/10.1093/NDT/GFAA29410.1093/NDT/GFAA294 ↗
4. Arici M, Altun B, Araz M, Atmaca A, Demir T, Ecder T, Guz G, Gogas Yavuz D, Yildiz A, Yilmaz T (2024) The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Front Med (Lausanne) 11:1384454. https://doi.org/10.3389/FMED.2024.1384454/XML10.3389/FMED.2024.1384454/XML ↗
5. Jankowski J, Floege J, Fliser D, Böhm M, Marx N (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143:1157. https://doi.org/10.1161/CIRCULATIONAHA.120.05068610.1161/CIRCULATIONAHA.120.050686 ↗
6. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42:152–161. https://doi.org/10.1093/EURHEARTJ/EHAA73610.1093/EURHEARTJ/EHAA736 ↗
7. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453–2463. https://doi.org/10.1093/EURHEARTJ/EHT18710.1093/EURHEARTJ/EHT187 ↗
8. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252–2263. https://doi.org/10.1056/NEJMOA211095610.1056/NEJMOA2110956 ↗
9. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229. https://doi.org/10.1056/NEJMOA202584510.1056/NEJMOA2025845 ↗
10. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474-484A. https://doi.org/10.1093/EURHEARTJ/EHAB77710.1093/EURHEARTJ/EHAB777 ↗
11. Fathima H, Pasha M, Khaleel M (2023) Estimation and validation of finerenone in dosage form and in bulk drug by spectrophotometric method. Asian J Res Chem 16:211–215. https://doi.org/10.52711/0974-4150.2023.0003310.52711/0974-4150.2023.00033 ↗
12. Rohde G, Loewen S, Heinig R (2021) Determination of finerenone – a novel, selective, nonsteroidal mineralocorticoid receptor antagonist – in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma. J Chromatogr B 1172:122643. https://doi.org/10.1016/J.JCHROMB.2021.12264310.1016/J.JCHROMB.2021.122643 ↗
13. Metkari VB, Deshmukh S, Gade MV (2024) Method development and validation of finerenone by RP-HPLC method. Int J Innov Res Technol 11:751–761
14. Somase K, Rishipathak D (2025) Finerenone API estimation using RP-HPLC technique and LC-MS characterization of its degradation products. Orient J Chem 41:528–540. https://doi.org/10.13005/OJC/41022210.13005/OJC/410222 ↗
15. Sreekanth M, Harika KSL (2024) A new validated method for the estimation of finerenone in bulk and pharmaceutical dosage form by UPLC. Int J Pharm Pharm Res 30:380–392
16. Murugesan A, Mathrusri AM (2021) Forced degradation studies for estimation of finerenone by RP-HPLC method. Acta Sci Pharm Sci 5:25–31. https://doi.org/10.31080/ASPS.2021.05.081810.31080/ASPS.2021.05.0818 ↗
17. Varade MM, Patil PR, Jadhav RG (2024) Rp-HPLC method development and validation of finerenone in bulk drug and its formulations. GSC Biological and Pharmaceutical Sciences 27:214–222. https://doi.org/10.30574/gscbps.2024.27.1.012810.30574/gscbps.2024.27.1.0128 ↗
18. Naazneen S (2024) An isocratic RP-HPLC method development and validation for the quantitative estimation of finerenone in solid dosage forms. Int J Multidiscip Res 6:1–9
19. Chepyala S, Medidi S, Malik J (2024) Development of a robust and reliable RP-HPLC method for the estimation of finerenone in tablet dosage form. Int J Drug Deliv Technol 14:703–70810.25258/ijddt.14.2.15 ↗
20. Loiseau A, Asila V, Boitel-Aullen G, Lam M, Salmain M, Boujday S (2019) Silver-based plasmonic nanoparticles for and their use in biosensing. Biosensors 9(2):78. https://doi.org/10.3390/BIOS902007810.3390/BIOS9020078 ↗
21. Willets KA, Van Duyne RP (2007) Localized surface plasmon resonance spectroscopy and sensing. Annu Rev Phys Chem 58:267–297. https://doi.org/10.1146/ANNUREV.PHYSCHEM.58.032806.104607/110.1146/ANNUREV.PHYSCHEM.58.032806.104607/1 ↗
22. Unser S, Bruzas I, He J, Sagle L (2015) Localized surface plasmon resonance biosensing: current challenges and approaches. Sensors 15:15684–15716. https://doi.org/10.3390/S15071568410.3390/S150715684 ↗
23. Rycenga M, Cobley CM, Zeng J, Li W, Moran CH, Zhang Q, Qin D, Xia Y (2011) Controlling the synthesis and assembly of silver nanostructures for plasmonic applications. Chem Rev 111:3669–3712. https://doi.org/10.1021/CR100275D/ASSET/CR100275D.FP.PNG_V0310.1021/CR100275D/ASSET/CR100275D.FP.PNG_V03 ↗
24. Mayer KM, Hafner JH (2011) Localized surface plasmon resonance sensors. Chem Rev 111:3828–3857. https://doi.org/10.1021/CR100313V/ASSET/CR100313V.FP.PNG_V0310.1021/CR100313V/ASSET/CR100313V.FP.PNG_V03 ↗
25. Navas MP, Soni RK (2015) Laser-generated bimetallic Ag-Au and Ag-Cu core-shell nanoparticles for refractive index sensing. Plasmonics 10:681–690. https://doi.org/10.1007/S11468-014-9854-5/FIGURES/1310.1007/S11468-014-9854-5/FIGURES/13 ↗
26. Lismont M, Dreesen L (2012) Comparative study of Ag and Au nanoparticles biosensors based on surface plasmon resonance phenomenon. Mater Sci Eng C 32:1437–1442. https://doi.org/10.1016/J.MSEC.2012.04.02310.1016/J.MSEC.2012.04.023 ↗
27. Ali MFB, Marzouq MA, Salman BI, Hussein SA (2019) Utility of surface plasmon resonance response of silver nanoparticles for assay of teicoplanin in human plasma using spectrofluorimetric technique. Microchem J 146:187–191. https://doi.org/10.1016/J.MICROC.2019.01.01610.1016/J.MICROC.2019.01.016 ↗
28. Shen H (2015) Plasmonic nanoparticles: towards the fabrication of biosensors. IOP Conf Ser Mater Sci Eng 87:012009. https://doi.org/10.1088/1757-899X/87/1/01200910.1088/1757-899X/87/1/012009 ↗
29. Anker JN, Hall WP, Lyandres O, Shah NC, Zhao J, Van Duyne RP (2008) Biosensing with plasmonic nanosensors. Nat Mater 7:442–453. https://doi.org/10.1038/NMAT216210.1038/NMAT2162 ↗
30. Vilela D, González MC, Escarpa A (2012) Sensing colorimetric approaches based on gold and silver nanoparticles aggregation: chemical creativity behind the assay. A review. Anal Chim Acta 751:24–43. https://doi.org/10.1016/J.ACA.2012.08.04310.1016/J.ACA.2012.08.043 ↗
31. Eker F, Akdaşçi E, Duman H, Bechelany M, Karav S (2025) Green synthesis of silver nanoparticles using plant extracts: a comprehensive review of physicochemical properties and multifunctional applications. Int J Mol Sci 26:6222. https://doi.org/10.3390/IJMS2613622210.3390/IJMS26136222 ↗
32. Bao Y, Tian C, Yu H, He J, Song K, Guo J, Zhou X, Zhuo O, Liu S (2022) In situ green synthesis of graphene oxide-silver nanoparticles composite with using gallic acid. Front Chem 10:905781. https://doi.org/10.3389/FCHEM.2022.905781/BIBTEX10.3389/FCHEM.2022.905781/BIBTEX ↗
33. Saad PG, Castelino RD, Ravi V, Al-Amri IS, Khan SA (2021) Green synthesis of silver nanoparticles using Omani pomegranate peel extract and two polyphenolic natural products: characterization and comparison of their antioxidant, antibacterial, and cytotoxic activities. Beni-Suef Univ J Basic Appl Sci 10:1–10. https://doi.org/10.1186/S43088-021-00119-6/TABLES/410.1186/S43088-021-00119-6/TABLES/4 ↗
34. Li D, Liu Z, Yuan Y, Liu Y, Niu F (2015) Green synthesis of gallic acid-coated silver nanoparticles with high antimicrobial activity and low cytotoxicity to normal cells. Process Biochem 50:357–366. https://doi.org/10.1016/J.PROCBIO.2015.01.00210.1016/J.PROCBIO.2015.01.002 ↗
35. Heinig R, Eissing T (2023) The pharmacokinetics of the nonsteroidal mineralocorticoid receptor antagonist finerenone. Clin Pharmacokinet 62:1673–1693. https://doi.org/10.1007/S40262-023-01312-910.1007/S40262-023-01312-9 ↗
36. International Council for Harmonisation (ICH) (1996) ICH Harmonised tripartite guideline: Validation of analytical procedures: Text and methodology Q2(R1). Current step 4 version. Parent Guidelines on Methodology
37. Evanoff DD, Chumanov G (2005) Synthesis and optical properties of silver nanoparticles and arrays. ChemPhysChem 6:1221–1231. https://doi.org/10.1002/CPHC.20050011310.1002/CPHC.200500113 ↗
38. Ault AP, Stark DI, Axson JL, Keeney JN, Maynard AD, Bergin IL, Philbert MA (2016) Protein corona-induced modification of silver nanoparticle aggregation in simulated gastric fluid. Environ Sci Nano 3:1510. https://doi.org/10.1039/C6EN00278A10.1039/C6EN00278A ↗
39. Piella J, Bastús NG, Puntes V (2017) Modeling the optical responses of noble metal nanoparticles subjected to physicochemical transformations in physiological environments: aggregation, dissolution and oxidation. Z Phys Chem 231:33–50. https://doi.org/10.1515/ZPCH-2016-087410.1515/ZPCH-2016-0874 ↗
40. UshaVipinachandran V, Rajendran S, Ali H, Ashokan I, Bhunia SK (2022) Citrate capped silver nanoparticles as an instantaneous colorimetric selective sensor for neomycin and thiamine in wastewater. New J Chem 46:14081–14090. https://doi.org/10.1039/D2NJ02174A10.1039/D2NJ02174A ↗
41. Gałuszka A, Migaszewski ZM, Konieczka P, Namieśnik J (2012) Analytical eco-scale for assessing the greenness of analytical procedures. TrAC Trends Anal Chem 37:61–72. https://doi.org/10.1016/J.TRAC.2012.03.01310.1016/J.TRAC.2012.03.013 ↗
42. Pena-Pereira F, Wojnowski W, Tobiszewski M (2020) AGREE—analytical greenness metric approach and software. Anal Chem 92:10076–10082. https://doi.org/10.1021/ACS.ANALCHEM.0C0188710.1021/ACS.ANALCHEM.0C01887 ↗